Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.
Read Full NewsIn children with difficult-to-treat glaucoma, a nonvalved implant yields sustained reductions in intraocular pressure and medication burden for up to 5 years.
A population-based study finds that children with spina bifida are more likely than their peers in the general population to develop chronic kidney disease and ESRD — and to do so at younger ages.
1.
Aster Whitefield Hospital, with 506 beds, opened.
2.
CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group
3.
A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.
4.
Depression risk higher among long-term breast cancer survivors than women without breast cancer history
5.
Pain’s Toll: Frailty Risk for Childhood Cancer Survivors
1.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
2.
Understanding the Importance of Knowing Your MCV Normal Range
3.
Fibroma: Understanding the Causes, Symptoms, and Treatment Options
4.
Learning from Uncommon Inherited Bleeding Disorder Presentations
5.
Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
2.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge